Cover Image
市場調查報告書

成藥、營養補充品:全球市場

Over-the-Counter (OTC) Drugs and Dietary Supplements: Global Markets

出版商 BCC Research 商品編碼 295754
出版日期 內容資訊 英文 150 Pages
訂單完成後即時交付
價格
Back to Top
成藥、營養補充品:全球市場 Over-the-Counter (OTC) Drugs and Dietary Supplements: Global Markets
出版日期: 2017年03月08日 內容資訊: 英文 150 Pages
簡介

全球成藥、營養補充品市場,2016年達到1,647億美元,預計至2021年擴大到2,208億美元。預計市場2016年∼2021年以6.0%的年複合成長率成長。

本報告提供全球成藥、營養補充品市場相關調查分析,市場概要,市場趨勢與預測,研究開發,主要企業簡介等系統性資訊。

第1章 簡介

第2章 摘要

第3章 概要

  • 成藥的進步
  • 成藥、營養補充品市場主要成長要素
  • 成藥產業的推動因素
  • 成藥、營養補充品的規則與法規
  • 成藥、營養補充品市場

第4章 全球成藥、營養補充品市場

  • 全球成藥、營養補充品市場
  • 地區的成藥、營養補充品市場
  • 全球成藥的銷售額預測:各治療分類
  • 全球成藥、營養補充品市場:各銷售場所
  • 全球成藥、營養補充品市場預測:各銷售商店

第5章 南北美洲的成藥、營養補充品市場

  • 北美的成藥、營養補充品市場
  • 美國的成藥、營養補充品
  • 美國的成藥的供應商生態系統

第6章 歐洲的成藥、營養補充品市場

  • BREXIT對歐洲成藥市場的影響
  • 歐洲的成藥、營養補充品市場
  • 英國的成藥市場
  • 德國的成藥、營養補充品市場

第7章 亞太地區的成藥、營養補充品市場

  • 亞太地區的成藥市場

第8章 全球成藥市場:各治療分類

  • OTC止痛藥/退燒藥市場
  • OTC抗組織胺藥,咳嗽、感冒藥市場
  • OTC腸胃藥產品市場
  • OTC皮膚病藥市場
  • OTC口腔醫療照護產品市場
  • OTC眼部護理產品市場預測
  • OTC戒煙產品市場
  • OTC營養補充品 (VMS) 市場
  • 全球市場預測

第9章 成藥產業發展藍圖

  • 成藥購買的實行
  • 成藥的藥局所扮演的角色
  • 成藥市場的法規影響
  • 市場普及、擴大的主要策略的舉措
  • 成藥產業的推動因素、障礙
  • 成藥、營養補充品產業的SWOT分析

第10章 企業簡介

第11章 附錄I

第12章 附錄II

第13章 附錄III

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHM050C

Report Highlights

The global market for over the counter (OTC) drugs and dietary supplements reached $164.7 billion in 2016 and should reach $220.8 billion in 2021, with a compound annual growth rate (CAGR) of 6.0%.

Report Includes

  • An overview of the global markets for OTC drugs and dietary supplements
  • Analyses of global market trends, with data from 2015, 2016, and projections of CAGRs through 2021
  • Information about how pharmacies affect the OTC drug market
  • Analysis of new developments that will provide an opportunity to manufacturers and marketers of OTC medicines and dietary supplements to expand organically
  • Updates on the latest merger and acquistion activity
  • Coverage of how point of sales and channels of distribution drive sales of OTC drugs and dietary supplements
  • A look at key strategic initiatives for market penetration and expansion
  • Company profiles of major players in the field

Report Scope

The report considers only western or modern drugs for this report and excludes any other type of drugs such as alternative therapies.

This study aims at understanding the dynamics and forecasts for OTC drugs and dietary supplements markets worldwide and provides key market propositions within the next five-year period.

The report covers developed and emerging markets in order to help readers understand:

  • The current state of the OTC drugs and dietary supplements market and the key markets for its future development.
  • New regulations that will influence the development of the OTC drugs and dietary supplements market.
  • Market drivers of and threats to the OTC drugs and dietary supplements industry.
  • Major regional trends in the global OTC drugs and dietary supplements market.

Analyst Credentials

With more than 10 years of experience with market research publishers, management consultants and government bodies, Anand Gijare specializes in predictive and exploratory research projects for market demand potential, sizing and perceptions, as well as in analyzing macro and micro markets in terms of key gaps and opportunities. His expertise includes market trends and drivers, competitive scenarios, value chain analysis and in-depth global market forecasts. He has worked on research studies across a variety of industrial sectors, including pharmaceuticals, healthcare, and information and communication technology.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • GLOBAL OTC DRUG MARKETS BY LEADING THERAPEUTIC SEGMENTS, 2016 THROUGH 2021
    • SUMMARY TABLE A: GLOBAL THERAPEUTIC MARKETS FOR OTC DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • SUMMARY FIGURE A: GLOBAL THERAPEUTIC MARKETS FOR OTC DRUGS, BY SEGMENT, 2015-2021 ($ MILLIONS)
  • GLOBAL DIETARY SUPPLEMENT MARKETS, 2016 THROUGH 2021
    • SUMMARY TABLE B: REGIONAL MARKETS FOR DIETARY SUPPLEMENTS, THROUGH 2021 ($ MILLIONS)
    • SUMMARY FIGURE B: REGIONAL MARKETS FOR DIETARY SUPPLEMENTS, 2015-2021 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • EVOLUTION OF OTC DRUGS
  • KEY GROWTH FACTORS FOR OTC DRUGS AND DIETARY SUPPLEMENT MARKETS
    • FIGURE 1: KEY GROWTH FACTORS FOR OTC DRUGS
  • INDUSTRY DRIVERS FOR OTC DRUGS
    • PREVALENCE OF SELF-CARE
    • BURDEN ON PUBLIC HEALTH SYSTEM
    • RETAIN MARKET LEADERSHIP
  • RULES AND REGULATIONS FOR OTC DRUGS AND DIETARY SUPPLEMENTS
    • REGULATIONS FOR OTC DRUGS
    • REGULATIONS FOR DIETARY SUPPLEMENTS
  • MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS
    • WELL-DEVELOPED MARKETS
    • DEVELOPING MARKETS
    • UNDER-DEVELOPED MARKETS

CHAPTER 4 - GLOBAL OTC DRUGS AND DIETARY SUPPLEMENT MARKETS

  • GLOBAL MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS 2016 THROUGH 2021
    • TABLE 1: GLOBAL MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS, THROUGH 2021 ($ MILLIONS)
  • REGIONAL MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENT MARKETS 2016 THROUGH 2021
    • TABLE 2: REGIONAL MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS THROUGH 2021 ($ MILLIONS)
  • GLOBAL SALES FORECAST FOR OTC DRUGS BY THERUPEUTIC CLASSIFICATION
    • TABLE 3: GLOBAL MARKET FOR OTC DRUGS, BY THERUPEUTIC CLASSIFICATION, THROUGH 2021 ($ MILLIONS)
  • GLOBAL OTC DRUGS AND DIETARY SUPPLEMENT MARKETS BY LOCATION OF SALES 2016 THROUGH 2021
    • TABLE 4: OTC DRUGS REVENUE BY LOCATION OF SALES, THROUGH 2021 ($ MILLIONS)
    • TABLE 5: DIETARY SUPPLEMENTS REVENUE BY LOCATION OF SALES, THROUGH 2021 ($ MILLIONS)
  • GLOBAL MARKET FORECAST FOR OTC DRUGS AND DIETARY SUPPLEMENTS BY SALES OUTLETS, THROUGH 2021

CHAPTER 5 - OTC DRUGS AND DIETARY SUPPLEMENT MARKETS IN THE AMERICAS

  • OTC DRUGS AND DIETARY SUPPLEMENT MARKETS IN NORTH AMERICA 2016 THROUGH 2021
    • NORTH AMERICA OTC DRUGS MARKETS 2016 THROUGH 2021
      • TABLE 6: NORTH AMERICA OTC DRUG MARKETS, THROUGH 2021 ($ MILLIONS)
    • NORTH AMERICA DIETARY SUPPLEMENT MARKETS 2016 THROUGH 2021
      • TABLE 7: NORTH AMERICA DIETARY SUPPLEMENT MARKETS, THROUGH 2021 ($ MILLIONS)
    • NORTH AMERICA OTC DRUGS MARKETS BY THERAPEUTIC CLASSIFICATION 2016 THROUGH 2021
      • TABLE 8: NORTH AMERICA MARKETS BY THERAPEUTIC CLASSIFICATION, THROUGH 2021 ($ MILLIONS)
  • OTC DRUGS AND DIETARY SUPPLEMENTS IN THE U.S.
    • NORTH AMERICA OTC DRUGS MARKETS BY THERAPEUTIC CLASSIFICATION 2016-2021
      • TABLE 8: NORTH AMERICA MARKETS BY THERAPEUTIC CLASSIFICATION, THROUGH 2021 ($ MILLIONS)
  • VENDOR ECOSYSTEM FOR OTC DRUGS IN THE U.S.
    • MULTINATIONAL OTC DRUG MANUFACTURERS
    • STORE BRANDS
    • FMCG COMPANIES
    • REGULATIONS AND APPROVAL PROCESS: THE U.S.
      • Drugs Developed Under the OTC Drug Monograph Process
        • OTC Drug Review
          • OTC Monograph
      • OTC Drugs Developed Through the NDA Process
      • Updated List of Prescription to Over-the-Counter (OTC) Switches
        • TABLE 9: UPDATED LIST OF RX-TO-OTC SWITCHES IN THE U.S. FROM 2001 TO 2016
    • THE U.S. NONPRESCRIPTION SAFE-USE REGULATORY EXPANSION (NSURE) INITIATIVE
    • THE U.S. OTC DRUGS AND DIETARY SUPPLEMENT MARKET 2016-2021
      • TABLE 10: THE U.S. OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFCATIONS, THROUGH 2021 ($ MILLIONS)
    • BRAZIL OTC DRUGS MARKET
    • BRAZIL OTC DRUGS MARKET 2016 THROUGH 2021
      • TABLE 11: BRAZIL OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 ($ MILLIONS)

CHAPTER 6 - THE OTC DRUG AND DIETARY SUPPLEMENT MARKETS IN EUROPE

  • BREXIT EFFECT ON THE OTC DRUG MARKET IN EUROPE
    • REGULATIONS AND APPROVAL PROCESS IN EUROPE
      • National Procedure
      • Decentralized Procedure
      • Mutual Recognition Procedure
      • Centralized Procedure
    • SMART REGULATION 2015: EUROPE AS A SINGLE MARKET
  • OTC DRUGS AND DIETARY SUPPLEMENT MARKETS IN EUROPE 2016 - 2021
    • EUROPEAN OTC DRUGS AND DIETARY SUPPLEMENT MARKETS 2016 - 2021
      • TABLE 12: EUROPEAN OTC DRUG MARKETS, THROUGH 2021 ($ MILLIONS)
    • OTC DRUGS AND DIETARY SUPPLEMENT MARKETS: WESTERN EUROPE THROUGH 2021
      • TABLE 13: EUROPEAN OTC DRUG MARKETS BY THERAPEUTIC CLASSIFCATIONS, THROUGH 2021 ($ MILLIONS)
  • THE U.K. OTC DRUG MARKET
    • THE REGULATIONS AND APPROVAL PROCESS IN THE U.K.
      • Better Regulation of Over-the-Counter Drugs Initiative (BROMI) U.K.
    • POM TO P RECLASSIFICATIONS UP TO OCTOBER 2016
      • TABLE 14: U.K. POM TO P RECLASSIFICATIONS UP TO OCTOBER 2016
      • TABLE 15: P TO GSL RECLASSIFICATIONS UP TO OCTOBER 2016
    • POM TO P RECLASSIFICATIONS IN THE U.K. APPROVED FROM 2010 TO 2015
      • TABLE 16: RECENT POM TO P RECLASSIFICATIONS AND NONPRESCRIPTION MARKETING AUTHORIZATIONS: U.K., 2010-2015
      • TABLE 17: RECENT P TO GSL RECLASSIFICATIONS AND NONPRESCRIPTION MARKETING AUTHORIZATIONS - U.K., 2011-2015
    • U.K. OTC DRUGS AND DIETARY SUPPLEMENT MARKET 2016 THROUGH 2021
      • TABLE 18: THE U.K. OTC DRUG MARKET, BY THERAPEUTIC CLASSIFICATION, THROUGH 2021 ($ MILLIONS)
  • GERMAN OTC DRUG AND DIETARY SUPPLEMENTS MARKET
    • THE REGULATIONS AND APPROVAL PROCESS IN GERMANY
    • OTC DRUG SWITCHES IN GERMANY FROM 2005 TO 2016
      • TABLE 19: OTC DRUG SWITCHES IN GERMANY FROM 2005 TO 2016
    • GERMAN OTC MARKET 2016 THROUGH 2021
      • TABLE 20: GERMANY OTC DRUG MARKETS BY THERAPEUTIC CLASSIFCATIONS, THROUGH 2021 ($ MILLIONS)
    • FRANCE'S OTC DRUGS MARKET 2016 THROUGH 2021
      • TABLE 21: FRANCE OTC DRUG MARKETS BY THERAPEUTIC CLASSIFCATIONS, THROUGH 2021 ($ MILLIONS)
    • OTC DRUGS AND DIETARY SUPPLEMENT MARKETS IN CENTRAL AND EASTERN EUROPE
      • TABLE 22: CCE OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFCATIONS, THROUGH 2021 ($ MILLIONS)
    • THE RUSSIAN OTC DRUG MARKET 2016 THROUGH 2021
      • TABLE 23: RUSSIAN OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 ($ MILLIONS)
    • THE POLISH OTC DRUG MARKET 2016 THROUGH 2021
      • TABLE 24: POLISH OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 ($ MILLIONS)

CHAPTER 7 - OTC DRUGS AND DIETARY SUPPLEMENT MARKETS IN ASIA-PACIFIC

  • APAC OTC DRUGS MARKETS 2016 THROUGH 2021
    • TABLE 25: APAC OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 ($ MILLIONS)
    • JAPAN'S OTC DRUGS MARKET
      • The Regulation and Approval Process in Japan
      • Reviews Conducted for OTC Drugs In Japan, by Fiscal Year
        • TABLE 26: REVIEWS CONDUCTED FOR OTC DRUGS IN JAPAN, BY FISCAL YEAR, 2011-2015
      • First Kind Pharmaceutical Newly Approved - Japan's OTC Pharmaceutical Sales System
        • TABLE 27: UPDATED LIST OF OTC TO FIRST KIND PHARMACEUTICAL DRUGS IN JAPAN, NOV. 2007-MARCH 2016
    • JAPAN'S OTC DRUGS MARKET 2016 THROUGH 2021
      • TABLE 28: JAPAN OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 ($ MILLIONS)
    • CHINA OTC DRUG MARKETS 2016 THROUGH 2021
    • THE REGULATION AND APPROVAL PROCESS: CHINA
      • New Amendments in Regulating Drug Advertising in 2015
    • CHINA - OTC DRUGS MARKET 2016 THROUGH 2021
      • TABLE 29: CHINA OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 ($ MILLIONS)
    • INDIA OTC DRUG MARKETS
    • INDIA: REGULATION AND APPROVAL PROCESSES
    • INDIA - OTC DRUGS MARKET 2016 THROUGH 2021
      • TABLE 30: INDIA OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 ($ MILLIONS)
    • AUSTRALIA AND NEW ZEALAND'S OTC DRUGS MARKET
      • Regulation and Approval Process: Australia
    • NEW ZEALAND
    • JOINT AUSTRALIAN AND NEW ZEALAND PHASED IMPLEMENTATION PLAN 2013
      • N2 Applications (Using OTC Monographs) Version1, September 2013
      • Level N3, N4 and N5 Applications
    • AUSTRALIA AND NEW ZEALAND: OTC DRUGS MARKET 2016 THROUGH 2021
      • TABLE 31: AUSTRALIA AND NEW ZEALAND OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 ($ MILLIONS)

CHAPTER 8 - GLOBAL MARKET FORECAST FOR OTC DRUGS BY THERUPEUTIC CLASSIFICATION

  • OTC ANALGESICS/ANTIPYRETICS MARKETS 2021
    • ACETAMINOPHEN
    • NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
    • MARKET FORECASTS 2016 THROUGH 2021
      • TABLE 32: GLOBAL MARKET FORECAST FOR OTC ANALGESICS AND ANTIPYRETICS, THROUGH 2021 ($ MILLIONS)
  • OTC ANTIHISTAMINE AND COUGH AND COLD DRUGS MARKETS 2021
    • ANTIHISTAMINES
    • COUGH AND COLD REMEDIES
      • Nasal Decongestants
      • Cough Remedies
    • GLOBAL MARKET FORECASTS THROUGH 2021
      • TABLE 33: GLOBAL MARKET FORECAST FOR OTC ANTIHISTAMINE AND COUGH AND COLD, THROUGH 2021 ($ MILLIONS)
  • OTC GASTROINTESTINAL PRODUCTS MARKETS 2021
    • GASTROINTESTINAL DISORDER TREATMENTS
      • Antacids
      • H2 Blockers
      • Proton Pump Inhibitors (PPIs)
    • GLOBAL MARKET FORECAST FOR THROUGH 2021
      • TABLE 34: GLOBAL MARKET FORECAST FOR OTC GASTROINTESTINAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • OTC DERMATOLOGICAL DRUGS MARKETS 2021
    • SKINCARE AND DERMATOLOGICAL DRUGS
      • Acne Treatments
      • Psoriasis
    • GLOBAL MARKET FORECAST THROUGH 2021
      • TABLE 35: GLOBAL MARKET FORECAST FOR OTC DERMATOLOGICAL DRUGS, THROUGH 2021 ($ MILLIONS)
  • OTC ORAL MEDICAL CARE PRODUCTS MARKETS 2021
    • ORAL MEDICAL CARE
      • Oral Debriding Agents and Wound Cleansers
      • Treatments for Dental Carries
      • Treatments on Gum Diseases
      • Treatments for Cold Sores
    • GLOBAL MARKET FORECAST FOR THROUGH 2021
      • TABLE 36: GLOBAL MARKET FORECAST FOR OTC ORAL MEDICAL CARE PRODUCTS THROUGH 2021 ($ MILLIONS)
  • GLOBAL MARKET FORECAST FOR OTC EYE CARE PRODUCTS
    • EYE CARE PRODUCTS
      • Treatments for Dry Eye
      • Ocular Allergy Symptoms
      • Ocular/Eye Vitamins
      • Eyelid Hygiene
      • Contact Lenses Solution
      • Dry Eye
    • GLOBAL MARKET FORECAST THROUGH 2021
      • TABLE 37: GLOBAL MARKET FORECAST FOR OTC EYE CARE PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • OTC SMOKING CESSATION PRODUCTS MARKETS 2021
    • SMOKING CESSATION
      • Nicotine Gum
      • Nicotine Lozenges
      • Nicotine Patch
    • GLOBAL MARKET FORECAST FOR OTC SMOKING CESSATION PRODUCTS BY REGION THROUGH 2021
      • TABLE 38: GLOBAL MARKET FORECAST FOR OTC SMOKING CESSATION PRODUCTS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • OTC DIETARY SUPPLEMENTS (VMS) MARKETS 2021
    • EATING DISORDERS
    • TREATMENTS FOR VITAMINS AND MINERAL DEFICIENCY
    • VITAMINS AND MINERAL SUPPLEMENTS (VMS)
  • GLOBAL MARKET FORECAST THROUGH 2021
    • TABLE 39: GLOBAL MARKET FORECAST FOR OTC DIETARY SUPPLEMENT PRODUCTS, BY REGION, THROUGH 2021 ($ MILLIONS)

CHAPTER 9 - OTC DRUG INDUSTRY ROADMAP

  • THE PRACTICE OF BUYING OTC DRUGS
  • ROLE OF PHARMACY IN OTC DRUGS
  • REGULATORY INFLUENCE ON OTC DRUG MARKET
  • KEY STRATEGIC INITIATIVES FOR MARKET PENETRATION AND EXPANSION
    • ACQUISITION OF MARKETING AUTHORIZATION: KEY MARKET PENETRATION AND EXPANSION STRATEGY
    • EXPANSIONS, PARTNERSHIPS AND JOINT VENTURES
    • THIRD-PARTY CONTRACTING
  • DRIVERS OF AND BARRIERS TO THE OTC DRUG INDUSTRY
    • RECENT DRIVERS FOR THE OTC DRUGS AND DIETARY SUPPLEMENT MARKET
  • STRENGTHS, WEAKNESSES, OPPORTUNITIES AND THREATS (SWOT) ANALYSIS OF THE OTC DRUG AND DIETARY SUPPLEMENT INDUSTRY
    • TABLE 40: SWOT ANALYSIS OF THE OTC DRUG AND DIETARY SUPPLEMENT INDUSTRY

CHAPTER 10 - COMPANY PROFILES

  • ALACER CORP.
  • ALCON INC.
  • ALFRESA PHARMA CORPORATION
  • ALKALON A/S
  • ALLIANCE HEALTHCARE
    • ALLIANCE HEALTHCARE DEUTSCHLAND
    • ALLIANCE HEALTHCARE FRANCE
  • ALLERGAN, PLC.
  • ALTICOR
    • NUTRILITE
  • ARKOPHARMA PHARMACEUTICAL LABORATORIES (LABORATOIRES PHARMACEUTIQUES)
  • ASPEN HOLDINGS
    • ASPEN PHARMACARE AUSTRALIA PTY. LTD.
  • BAUSCH & LOMB
  • BAYER HEALTHCARE AG
  • BOEHRINGER INGELHEIM GMBH
  • CARMA LABORATORIES, INC.
  • CHATTEM INC.
  • CILAG AG
  • COLGATE-PALMOLIVE COMPANY
  • DAIICHI SANKYO CO., LTD.
  • DERMA SCIENCES
  • EYESCIENCE LABS
  • FERTIN PHARMA A/S
  • GABA GMBH, PC
    • GABA SCHWEIZ
  • GALDERMA S.A.
  • GEMINI PHARMACEUTICALS, INC.
  • GENOMMA LAB INTERNATIONAL
    • GENOMMA LAB USA
  • GLAXOSMITHKLINE PLC
  • HISAMITSU PHARMACEUTICAL CO., INC.
  • JOHNSON & JOHNSON
  • KOWA COMPANY, LTD.
  • LAKE CONSUMER PRODUCTS, INC.
  • MANX HEALTHCARE LIMITED
  • MCM KLOSTERFRAU VERTRIEBS GMBH (KLOSTERFRAU HEALTHCARE GROUP)
  • MEDA AB
  • MELALEUCA, INC.
  • MERCK CORPORATE HEADQUARTERS
    • MERCK CANADA
    • MERCK CHINA
  • MERZ PHARMA
  • MOCHIDA PHARMACEUTICAL CO., LTD.
  • NEPENTES SA/NEPENTES PHARMA SP. Z O.O.
  • NEUTROGENA CORP.
  • NORTHEAST PHARMACEUTICAL GROUP CO. LTD
  • NOVARTIS INTERNATIONAL AG
  • NOW FOODS
  • PERRIGO PLC
  • PFIZER INC.
  • PGT HEALTHCARE (DIVISION OF PROCTER & GAMBLE)
  • PHARMAVITE LLC
  • PIERRE FABRE PHARMACEUTICALS INC.
  • PIRAMAL HEALTHCARE LTD
  • PRESTIGE BRANDS HOLDINGS, INC.
  • RECKITT BENCKISER PLC.
    • RECKITT BENCKISER (NORTH AMERICA) INC.
  • RECORDATI PHARMA GMBH
  • REVOLYMER (U.K.) LTD
  • SAGE PRODUCTS LLC
  • SANOFI
  • SATO PHARMACEUTICAL CO., LTD.
  • SHAKLEE CORPORATION
  • STADA ARZNEIMITTEL AG
  • SWISSE WELLNESS PTY LTD.
  • TAISHO PHARMACEUTICAL HOLDINGS
  • TAKEDA PHARMACEUTICALS LTD.
  • TISSO NATURPRODUKTE GMBH
  • WELLSPRING PHARMACEUTICAL CORPORATION
  • ZEAVISION, LLC

CHAPTER 11 - APPENDIX I

  • MARKET DEFINITIONS
    • OTC DRUGS
    • DIETARY SUPPLEMENTS (VMS)
  • COMMON ADMINISTRATION METHODS FOR OTC DRUGS
    • TOPICAL ADMINISTRATION
      • Lotion
      • Cream
      • Ointment
      • Gel
      • Transdermal Patch
    • ORAL ADMINISTRATION
      • Tablets
      • Capsules
      • Medicinal Syrups
      • Medicated Chewing Gums

CHAPTER 12 - APPENDIX II

  • SMOKING CESSATION INITIATIVES
    • HIGH RATE OF SMOKERS QUITTING IN DEVELOPED COUNTRIES
    • DECREASE IN SMOKING RATES AT SATURATION POINT IN DEVELOPED MARKETS
    • SMOKING RATES ARE INCREASING IN DEVELOPING MARKETS
    • STRATEGIC INITIATIVES TO INCREASE SMOKING CESSATION IN DEVELOPING COUNTRIES
    • DEVELOPING AND POOR COUNTRIES SIGN WHO FCTC TREATY
    • WHO FCTC PROGRESS REPORT 2012
      • TABLE 41: ARTICLES REPORTED TO HAVE HIGHEST IMPLEMENTATION RATES IN 2012 WHO FCTC PROGRESS REPORT (%)
      • TABLE 42: ARTICLES REPORTED MODERATE IMPLEMENTATION RATES: 2012 WHO FCTC PROGRESS REPORT (%)
      • TABLE 43: ARTICLES REPORTED LOWEST IMPLEMENTATION RATES: 2012 WHO FCTC PROGRESS REPORT (%)
      • FIGURE 2: GLOBAL IMPLEMENTATION OF ARTICLES OF 2012 WHO FCTC PROGRESS REPORT (%)
      • TABLE 44: GLOBAL IMPLEMETATION OF FCTC ARTICLES: 2012 REPORT
      • Implementation of Article 14 in 2012
        • TABLE 45: GLOBAL IMPLEMENTATION OF ARTICLE 14 OF FCTC
      • Political and Legal Interventions Influence Markets
        • TABLE 46: INITIATIVES IMPLEMENTED BY PARTIES TO FCTC TREATY IN 2012 (%)
      • Socioeconomic Factors of Smoking
        • TABLE 47: PROJECTED GLOBAL CAUSE OF DEATH BY DISEASE (%)
        • TABLE 48: PUBLIC HEALTH BURDEN DUE TO SMOKING-RELATED DISEASES ($ BILLIONS)
      • Technological Developments Concerning Smoking
        • FIGURE 3: ONGOING STUDIES, BY REGION (NO. OF STUDIES)

CHAPTER 13 - APPENDIX III

  • OTC MARKETS 2013 THROUGH 2018
    • TABLE 49: GLOBAL MARKET FOR OTC DRUGS AND DIETARY SUPPLEMENTS THROUGH 2018 ($ MILLIONS)
    • FIGURE 4: GLOBAL MARKET FOR OTC DRUGS AND DIETARY SUPPLEMENTS, 2011-2018 ($ MILLIONS)
  • HIGHLIGHTS OF THE YEAR 2012
  • TRENDS IN OTC DRUGS AND DIETARY SUPPLEMENTS THROUGH 2018
  • FORECAST TRENDS IN OTC DRUGS BY THERAPEUTIC CLASS THROUGH 2018

LIST OF TABLES

  • SUMMARY TABLE A: GLOBAL THERAPEUTIC MARKETS FOR OTC DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • SUMMARY TABLE B: REGIONAL MARKETS FOR DIETARY SUPPLEMENTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 1: GLOBAL MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 2: REGIONAL MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS THROUGH 2021 ($ MILLIONS)
    • TABLE 3: GLOBAL MARKET FOR OTC DRUGS, BY THERUPEUTIC CLASSIFICATION, THROUGH 2021 ($ MILLIONS)
    • TABLE 4: OTC DRUGS REVENUE BY LOCATION OF SALES, THROUGH 2021 ($ MILLIONS)
    • TABLE 5: DIETARY SUPPLEMENTS REVENUE BY LOCATION OF SALES, THROUGH 2021 ($ MILLIONS)
    • TABLE 6: NORTH AMERICA OTC DRUG MARKETS, THROUGH 2021 ($ MILLIONS)
    • TABLE 7: NORTH AMERICA DIETARY SUPPLEMENT MARKETS, THROUGH 2021 ($ MILLIONS)
    • TABLE 8: NORTH AMERICA MARKETS BY THERAPEUTIC CLASSIFICATION, THROUGH 2021 ($ MILLIONS)
    • TABLE 8: NORTH AMERICA MARKETS BY THERAPEUTIC CLASSIFICATION, THROUGH 2021 ($ MILLIONS)
    • TABLE 9: UPDATED LIST OF RX-TO-OTC SWITCHES IN THE U.S. FROM 2001 TO 2016
    • TABLE 10: THE U.S. OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFCATIONS, THROUGH 2021 ($ MILLIONS)
    • TABLE 11: BRAZIL OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 ($ MILLIONS)
    • TABLE 12: EUROPEAN OTC DRUG MARKETS, THROUGH 2021 ($ MILLIONS)
    • TABLE 13: EUROPEAN OTC DRUG MARKETS BY THERAPEUTIC CLASSIFCATIONS, THROUGH 2021 ($ MILLIONS)
    • TABLE 14: U.K. POM TO P RECLASSIFICATIONS UP TO OCTOBER 2016
    • TABLE 15: P TO GSL RECLASSIFICATIONS UP TO OCTOBER 2016
    • TABLE 16: RECENT POM TO P RECLASSIFICATIONS AND NONPRESCRIPTION MARKETING AUTHORIZATIONS: U.K., 2010-2015
    • TABLE 17: RECENT P TO GSL RECLASSIFICATIONS AND NONPRESCRIPTION MARKETING AUTHORIZATIONS - U.K., 2011-2015
    • TABLE 18: THE U.K. OTC DRUG MARKET, BY THERAPEUTIC CLASSIFICATION, THROUGH 2021 ($ MILLIONS)
    • TABLE 19: OTC DRUG SWITCHES IN GERMANY FROM 2005 TO 2016
    • TABLE 20: GERMANY OTC DRUG MARKETS BY THERAPEUTIC CLASSIFCATIONS, THROUGH 2021 ($ MILLIONS)
    • TABLE 21: FRANCE OTC DRUG MARKETS BY THERAPEUTIC CLASSIFCATIONS, THROUGH 2021 ($ MILLIONS)
    • TABLE 22: CCE OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFCATIONS, THROUGH 2021 ($ MILLIONS)
    • TABLE 23: RUSSIAN OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 ($ MILLIONS)
    • TABLE 24: POLISH OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 ($ MILLIONS)
    • TABLE 25: APAC OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 ($ MILLIONS)
    • TABLE 26: REVIEWS CONDUCTED FOR OTC DRUGS IN JAPAN, BY FISCAL YEAR, 2011-2015
    • TABLE 27: UPDATED LIST OF OTC TO FIRST KIND PHARMACEUTICAL DRUGS IN JAPAN, NOV. 2007-MARCH 2016
    • TABLE 28: JAPAN OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 ($ MILLIONS)
    • TABLE 29: CHINA OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 ($ MILLIONS)
    • TABLE 30: INDIA OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 ($ MILLIONS)
    • TABLE 31: AUSTRALIA AND NEW ZEALAND OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 ($ MILLIONS)
    • TABLE 32: GLOBAL MARKET FORECAST FOR OTC ANALGESICS AND ANTIPYRETICS, THROUGH 2021 ($ MILLIONS)
    • TABLE 33: GLOBAL MARKET FORECAST FOR OTC ANTIHISTAMINE AND COUGH AND COLD, THROUGH 2021 ($ MILLIONS)
    • TABLE 34: GLOBAL MARKET FORECAST FOR OTC GASTROINTESTINAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 35: GLOBAL MARKET FORECAST FOR OTC DERMATOLOGICAL DRUGS, THROUGH 2021 ($ MILLIONS)
    • TABLE 36: GLOBAL MARKET FORECAST FOR OTC ORAL MEDICAL CARE PRODUCTS THROUGH 2021 ($ MILLIONS)
    • TABLE 37: GLOBAL MARKET FORECAST FOR OTC EYE CARE PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 38: GLOBAL MARKET FORECAST FOR OTC SMOKING CESSATION PRODUCTS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 39: GLOBAL MARKET FORECAST FOR OTC DIETARY SUPPLEMENT PRODUCTS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 40: SWOT ANALYSIS OF THE OTC DRUG AND DIETARY SUPPLEMENT INDUSTRY
    • TABLE 41: ARTICLES REPORTED TO HAVE HIGHEST IMPLEMENTATION RATES IN 2012 WHO FCTC PROGRESS REPORT (%)
    • TABLE 42: ARTICLES REPORTED MODERATE IMPLEMENTATION RATES: 2012 WHO FCTC PROGRESS REPORT (%)
    • TABLE 43: ARTICLES REPORTED LOWEST IMPLEMENTATION RATES: 2012 WHO FCTC PROGRESS REPORT (%)
    • TABLE 44: GLOBAL IMPLEMETATION OF FCTC ARTICLES: 2012 REPORT
    • TABLE 45: GLOBAL IMPLEMENTATION OF ARTICLE 14 OF FCTC
    • TABLE 46: INITIATIVES IMPLEMENTED BY PARTIES TO FCTC TREATY IN 2012 (%)
    • TABLE 47: PROJECTED GLOBAL CAUSE OF DEATH BY DISEASE (%)
    • TABLE 48: PUBLIC HEALTH BURDEN DUE TO SMOKING-RELATED DISEASES ($ BILLIONS)
    • TABLE 49: GLOBAL MARKET FOR OTC DRUGS AND DIETARY SUPPLEMENTS THROUGH 2018 ($ MILLIONS)

LIST OF FIGURES

  • SUMMARY FIGURE A: GLOBAL THERAPEUTIC MARKETS FOR OTC DRUGS, BY SEGMENT, 2015-2021 ($ MILLIONS)
  • SUMMARY FIGURE B: REGIONAL MARKETS FOR DIETARY SUPPLEMENTS, 2015-2021 ($ MILLIONS)
    • FIGURE 1: KEY GROWTH FACTORS FOR OTC DRUGS
    • FIGURE 2: GLOBAL IMPLEMENTATION OF ARTICLES OF 2012 WHO FCTC PROGRESS REPORT (%)
    • FIGURE 3: ONGOING STUDIES, BY REGION (NO. OF STUDIES)
    • FIGURE 4: GLOBAL MARKET FOR OTC DRUGS AND DIETARY SUPPLEMENTS, 2011-2018 ($ MILLIONS) 159
Back to Top